• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迟发性综合征的分类与治疗

Classification and treatment of tardive syndromes.

作者信息

Fernandez Hubert H, Friedman Joseph H

机构信息

Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA.

出版信息

Neurologist. 2003 Jan;9(1):16-27. doi: 10.1097/01.nrl.0000038585.58012.97.

DOI:10.1097/01.nrl.0000038585.58012.97
PMID:12801428
Abstract

BACKGROUND

Tardive syndromes are a group of delayed-onset abnormal involuntary movement disorders induced by a dopamine receptor blocking agent. There are several phenomenologically distinct types of TS.

REVIEW SUMMARY

The term tardive dyskinesia has been used to refer to the TS that presents with rapid, repetitive, stereotypic movements mostly involving the oral, buccal, and lingual areas. Tardive dystonia can be focal, segmental, or generalized. It commonly affects the face and neck followed by the arms and trunk. It usually results in retrocollis when it involves the neck and trunk arching backwards when it involves the trunk. Tardive akathisia is characterized by a feeling of inner restlessness and jitteriness with an inability to sit or stand still. Other tardive syndromes include tardive tics, myoclonus, tremor, and withdrawal-emergent syndrome. It remains unclear whether tardive parkinsonism truly exists. The only way to prevent TS is to avoid its etiologic agents. Chronic use of dopamine receptor blocking agents should be limited as much as possible to patients with chronic psychoses. In general, for mild TS, reducing the neuroleptic dose, switching to an atypical agent, or discontinuing antipsychotic treatment altogether in the hope of facilitating remission is recommended. For moderate to severe TS, tetrabenazine or reserpine may be the most effective agent. Neuroleptics should be resumed to treat TD in the absence of active psychosis only as a last resort for persistent, disabling, and treatment-resistant TD.

CONCLUSIONS

The severity of the TS and the absolute need for antipsychotic therapy often dictate the treatment approach for this disorder.

摘要

背景

迟发性综合征是一组由多巴胺受体阻断剂诱发的迟发性异常不自主运动障碍。迟发性综合征有几种在现象学上不同的类型。

综述总结

迟发性运动障碍一词已被用于指代主要表现为快速、重复、刻板运动,大多累及口腔、颊部和舌部区域的迟发性综合征。迟发性肌张力障碍可以是局灶性、节段性或全身性的。它通常影响面部和颈部,其次是手臂和躯干。当累及颈部时通常导致颈后倾,当累及躯干时导致躯干向后拱起。迟发性静坐不能的特征是内心不安和紧张感,无法安静地坐着或站着。其他迟发性综合征包括迟发性抽搐、肌阵挛、震颤和撤药后出现的综合征。迟发性帕金森症是否真的存在仍不清楚。预防迟发性综合征的唯一方法是避免其病因。多巴胺受体阻断剂的长期使用应尽可能限于患有慢性精神病的患者。一般来说,对于轻度迟发性综合征,建议减少抗精神病药物剂量、换用非典型药物或完全停用抗精神病药物治疗以期促进缓解。对于中度至重度迟发性综合征,丁苯那嗪或利血平可能是最有效的药物。仅在作为治疗持续、致残且难治的迟发性运动障碍的最后手段时,才应在无活动性精神病的情况下恢复使用抗精神病药物来治疗迟发性运动障碍。

结论

迟发性综合征的严重程度以及对抗精神病治疗的绝对需求通常决定了这种疾病的治疗方法。

相似文献

1
Classification and treatment of tardive syndromes.迟发性综合征的分类与治疗
Neurologist. 2003 Jan;9(1):16-27. doi: 10.1097/01.nrl.0000038585.58012.97.
2
The nosology of tardive syndromes.迟发性综合征的分类学。
J Neurol Sci. 2018 Jun 15;389:10-16. doi: 10.1016/j.jns.2018.02.008. Epub 2018 Feb 6.
3
Spectrum of tardive syndromes: clinical recognition and management.迟发性综合征的范围:临床识别与管理。
Postgrad Med J. 2011 Feb;87(1024):132-41. doi: 10.1136/pgmj.2010.103234. Epub 2010 Dec 3.
4
Setting the record straight: The nosology of tardive syndromes.正本清源:迟发性综合征的分类学。
Parkinsonism Relat Disord. 2019 Feb;59:146-150. doi: 10.1016/j.parkreldis.2018.11.025. Epub 2018 Nov 28.
5
Tardive dyskinesia.迟发性运动障碍
Am J Hosp Pharm. 1976 May;33(5):481-6.
6
Distinguishing akathisia and tardive dyskinesia: a review of the literature.区分静坐不能和迟发性运动障碍:文献综述
J Clin Psychopharmacol. 1983 Dec;3(6):343-50.
7
[Treatment of tardive dyskinesia caused by neuroleptics].[抗精神病药物所致迟发性运动障碍的治疗]
Riv Neurol. 1984 May-Jun;54(3):199-215.
8
[Two cases of tardive Tourette syndrome].[迟发性抽动秽语综合征两例]
Seishin Shinkeigaku Zasshi. 2006;108(5):459-65.
9
The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.甲氧氯普胺所致迟发性运动障碍和急性锥体外系运动障碍的患病率。
Arch Intern Med. 1993 Jun 28;153(12):1469-75.
10
Tardive tremor.迟发性震颤
Mov Disord. 1992;7(1):53-7. doi: 10.1002/mds.870070110.

引用本文的文献

1
Management of Tardive Syndrome: Medications and Surgical Treatments.迟发性运动障碍的治疗:药物治疗和手术治疗。
Neurotherapeutics. 2020 Oct;17(4):1694-1712. doi: 10.1007/s13311-020-00898-3.
2
Calcium channel blockers for antipsychotic-induced tardive dyskinesia.用于抗精神病药物所致迟发性运动障碍的钙通道阻滞剂。
Cochrane Database Syst Rev. 2018 Mar 26;3(3):CD000206. doi: 10.1002/14651858.CD000206.pub4.
3
Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
使用甲氧氯普胺的不同年龄和性别组中报告的神经学药物不良反应的发病时间:对全球数据库Vigibase®的分析。
Eur J Clin Pharmacol. 2018 May;74(5):627-636. doi: 10.1007/s00228-017-2407-z. Epub 2017 Dec 30.
4
Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.大鼠纹状体中细胞因子水平的改变:可能参与抗精神病药物诱发的空嚼运动。
Neurochem Res. 2016 Sep;41(9):2481-9. doi: 10.1007/s11064-016-1961-6. Epub 2016 May 26.
5
High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.高剂量吡哆醇治疗迟发性运动障碍:临床病例及文献综述
Ther Adv Psychopharmacol. 2016 Apr;6(2):152-6. doi: 10.1177/2045125315616738. Epub 2015 Dec 14.
6
An update on tardive dyskinesia: from phenomenology to treatment.迟发性运动障碍的最新进展:从现象学到治疗
Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12;3. doi: 10.7916/D88P5Z71. Print 2013.
7
Systematic drug repositioning based on clinical side-effects.基于临床副作用的系统药物再定位。
PLoS One. 2011;6(12):e28025. doi: 10.1371/journal.pone.0028025. Epub 2011 Dec 21.
8
Rapid response of disabling tardive dyskinesia to amantadine: a case report.金刚烷胺对迟发性运动障碍的快速缓解作用:一例报告
Prim Care Companion CNS Disord. 2011;13(3). doi: 10.4088/PCC.10l01098.
9
Tardive Dystonia.迟发性肌张力障碍
Curr Treat Options Neurol. 2005 May;7(3):231-236. doi: 10.1007/s11940-005-0016-0.